Ind-Swift Laboratories reports FY23 PAT at Rs. 42.47 Cr

The company reported lifetime high EBIDTA of Rs. 250 crores

Hikal posts FY23 PAT at Rs. 36 Cr

Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22

Eugia Pharma receives USFDA approval for Carboprost Tromethamine Injection

The product is expected to be launched in June 2023

Supriya Lifescience Limited appoints of Dr. Shekhar Bhirud as President – Business Development, Strategy and R&D

Health Minister Mandaviya inaugurates 8th International Conference on Pharma and Medical Device Sector

Indian government seeks to promote collaboration with stakeholders and harness potential for achieving growth and development of sector

Labindia partners with Hamilton Laboratory to launch ‘Labindia Hamilton’

Product deliveries scheduled in Q3 of 2023

Lincoln Pharmaceuticals posts FY23 PAT at Rs. 72.90 Cr

For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year

Venus Remedies gets Kenyan GMP certification for its manufacturing facilities in Baddi

The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans

Shilpa Medicare Analytical Services Division gets VAI status from USFDA after GMP inspection

This is the second US FDA GMP inspection of this facility within one year

Agilent to appeal patent office decision on CRISPR gRNA patents

Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination